Tabomedex Biosciences, Inc.
Boston
About Tabomedex Biosciences, Inc.
Tabomedex focuses on the R&D of new drugs related to type 2 diabetes. They mainly study the mechanism of action of MK2 and achieve the effect of controlling blood glucose level by inhibiting MK2, namely inhibiting the effect of downstream avtivating enzymes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $5.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Aug 2020)
- Website: tabomedex.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/tabomedex-biosciences-inc-695 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.